|Day Low/High||513.64 / 517.46|
|52 Wk Low/High||250.21 / 532.57|
The RMPIA also tops other indexes for year, shooting ahead 29%.
The average declined in October, but it was less than that hit took by the major indexes.
TMO has one of the most stable-looking uptrends around.
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
The charts of the life sciences company suggest its stock could make a large upside move.
The markets are really in the hands of Washington right now, and Washington is in the hands of the virus.
This list is not a buy list but a list of stocks that have been brought to new heights.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
After a strong day for fixed-income markets, let's learn from 2008 how to play this volatility.
The pace of the selloff in shares of the maker of lab equipment has begun to slow and that is a positive.
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
It's no secret that the Fed would like to get out of the short-term repo business.
The charts of TMO are positive.
The Defense Department's potential $10 billion award for their cloud computing contract is a never ending saga with Microsoft and Amazon as finalists.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Watch closely as the government opens a broad antitrust investigation into unidentified leading online technology platforms
United Parcel Service EPS: beat Revs: beat, +3.4% y/y Record profit across all segments Raised guidance AT&T EPS: in line Revs: in line, +15.3% y/y Subscriber losses Raised guidance for free cash flow General Dynamics EPS: beat Revs: beat, +4.0%...
Bitcoin, the most famous of all crypto-currencies, has enjoyed something of a rebound of late.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
I think we can all agree that there will be no increase made to the Fed Funds Rate today.
Let's check the charts and indicators.